Abstract: A method to produce a chimeric protein having a flavivirus backbone and portions dengue virus is provided. The flavivirus envelope protein, such as from yellow fever virus 17D vaccine strain, is modified replacing amino acids surrounding the fusion loop of the flavivirus backbone with corresponding amino acids from the dengue virus envelope protein. The chimeric protein is useful as a vaccine to stimulate an immune response against DENV infection, thereby producing broadly neutralizing (protective) antibodies against dengue virus and reduce the induction of non-neutralizing antibodies that will cause enhancement.

Abstract: The invention pertains to inhibitors bindable to regions of a virus. More particularly, the invention relates to inhibitors bindable to regions of flaviviral envelope glycoprotein, or flaviviral virus E protein, a class II viral E protein. Even more particularly, the invention relates to peptides inhibitory to virus-to-cell fusion and virus entry into animal cells. The invention also contains methods of determining said inhibitors, bindable to regions of the flaviviral E protein complex, (e.g., those of dengue and zika viruses) as candidates for in vivo anti-viral compounds that are also resistant to degradation by peptidases and thus extraordinarily suitable for oral, in addition to other, routes of administration.

Abstract: A method to produce a chimeric protein having a Flavivirus backbone and portions dengue virus is provided. The Flavivirus envelope protein, such as from yellow fever virus 17D vaccine strain, is modified replacing amino acids surrounding the fusion loop of the Flavivirus backbone with corresponding amino acids from the dengue virus envelope protein. The chimeric protein is useful as a vaccine to stimulate an immune response against DENV infection, thereby producing broadly neutralizing (protective) antibodies against dengue virus and reduce the induction of non-neutralizing antibodies that will cause enhancement.

Abstract: Described here is a method to produce a chimeric protein having portions of yellow fever virus and dengue virus. A small portion of the yellow fever virus 17D vaccine strain envelope protein (or other related flavivirus) can be replaced by the corresponding portion from the dengue virus envelope protein. In some embodiments the chimeric protein may be used to create a treatment composition for DENV infection. In others, the chimeric protein may be used to create a vaccine that will induce broadly protective antibodies against dengue virus and reduce the induction of non-neutralizing antibodies that will cause enhancement.

Abstract: The invention pertains to inhibitors bindable to regions of a virus. More particularly, the invention relates to inhibitors bindable to regions of flaviviral envelope glycoprotein, or flaviviral virus E protein, a class II viral E protein. Even more particularly, the invention relates to peptides inhibitory to virus-to-cell fusion and virus entry into animal cells. The invention also contains methods of determining said inhibitors, bindable to regions of the flaviviral E protein complex, (e.g., those of dengue and zika viruses) as candidates for in vivo anti-viral compounds that are also resistant to degradation by peptidases and thus extraordinarily suitable for oral, in addition to other, routes of administration.

Abstract: Described here is a method to produce a chimeric protein having portions of yellow fever virus and dengue virus. A small portion of the yellow fever virus 17D vaccine strain envelope protein (or other related flavivirus) can be replaced by the corresponding portion from the dengue virus envelope protein. In some embodiments the chimeric protein may be used to create a treatment composition for DENV infection. In others, the chimeric protein may be used to create a vaccine that will induce broadly protective antibodies against dengue virus and reduce the induction of non-neutralizing antibodies that will cause enhancement.

Abstract: Described here is a method to produce a chimeric protein having portions of yellow fever virus and dengue virus. A small portion of the yellow fever virus 17D vaccine strain envelope protein (or other related flavivirus) can be replaced by the corresponding portion from the dengue virus envelope protein. In some embodiments the chimeric protein may be used to create a treatment composition for DENV infection. In others, the chimeric protein may be used to create a vaccine that will induce broadly protective antibodies against dengue virus and reduce the induction of non-neutralizing antibodies that will cause enhancement.

Abstract: The invention relates peptide entry inhibitors and methods of determining such inhibitors that are bindable to regions of viruses having class II E proteins, such as the dengue virus E protein, as candidates for in vivo anti-viral compounds.

Abstract: The invention relates peptide entry inhibitors and methods of determining such inhibitors that are bindable to regions of viruses having class II E proteins, such as the dengue virus E protein, as candidates for in vivo anti-viral compounds.

Abstract: The invention relates peptide entry inhibitors and methods of determining such inhibitors that are bindable to regions of viruses having class II E proteins, such as the dengue virus E protein, as candidates for in vivo anti-viral compounds.

Abstract: The invention relates peptide entry inhibitors and methods of determining such inhibitors that are bindable to regions of viruses having class II E proteins, such as the dengue virus E protein, as candidates for in vivo anti-viral compounds.

Abstract: The invention relates chemical compound entry inhibitors and methods of determining such inhibitors that interact with regions of viruses, such as the dengue virus, as candidates for in vivo anti-viral compounds.

Abstract: Methods to facilitate delivering of materials into biological systems using sonic energy. The processes include a method of controllably disrupting cell membranes and/or cell walls in biological cells using sonic energy, methods of introducing materials into biological cells using sonic energy, and methods of correlating sonic energy exposure to material transport efficiency into biological cells.